Brukinsa Approved for Relapsed, Refractory Mantle Cell Lymphoma
MONDAY, Nov. 18, 2019 — Brukinsa (zanubrutinib), a kinase inhibitor, has been granted accelerated approval for the treatment of adults with mantle cell lymphoma who have received at least one previous therapy, the U.S. Food and Drug Administration announced last week. The recommended dose of Brukinsa capsules is 160 mg orally twice daily or 320… Read More »